Sandoz Denosumab Biosimilar Progressing Faster Than Anticipated

Novartis Unit Developing Denosumab For Osteoporosis

 
• By Dean Rudge

Sandoz announced more than a year ago that its GP2411 biosimilar denosumab candidate had entered the clinic. Management provided an update on its progress at the recent Virtual Meet Novartis Management Investor Event.

Businessmen_Leapfrog
Sandoz believes its biosimilar program is the most advanced globally • Source: Shutterstock

More from Biosimilars

More from Products